VOGLI GM 1 TAB 10 S

About

VOGLI GM 1 TAB is a combination medication designed for the comprehensive management of type 2 diabetes mellitus. It typically combines an alpha-glucosidase inhibitor (like Voglibose), a sulfonylurea (like Glimepiride), and a biguanide (like Metformin). This multi-pronged approach targets different aspects of glucose metabolism: Voglibose delays carbohydrate absorption from the gut, Metformin reduces hepatic glucose production and improves insulin sensitivity, while Glimepiride stimulates insulin secretion from the pancreas. This synergistic action helps achieve better glycemic control, particularly by reducing postprandial glucose excursions and overall fasting blood sugar levels.

The formulation is indicated for adult patients whose blood sugar levels are not adequately controlled by monotherapy or dual therapy, or as an initial therapy in certain cases. It aims to lower HbA1c levels, thereby reducing the risk of long-term diabetic complications such as cardiovascular disease, neuropathy, and nephropathy. Regular monitoring of blood glucose and HbA1c is essential to assess treatment efficacy and adjust dosages as needed under medical supervision.

Uses

• Management of type 2 diabetes mellitus.
• Improved overall glycemic control in adults.
• Effective reduction of postprandial blood glucose levels.
• When monotherapy or dual therapy is insufficient.

Directions For Use

Take this medication orally with meals, as directed by your physician. Do not crush or chew the tablets.

Benefits

• Comprehensive blood glucose control.
• Significant reduction in HbA1c levels.
• Effective management of post-meal sugar spikes.
• Improved insulin sensitivity and utilization.
• Reduced risk of long-term diabetic complications.
• Synergistic action of multiple antidiabetic agents.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Flatulence
• Hypoglycemia (low blood sugar)
• Headache
• Dizziness
• Metallic taste
• Skin rash
• Weight gain
• Lactic acidosis (rare, serious)
• Vitamin B12 deficiency (with long-term Metformin)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can significantly increase the risk of hypoglycemia and lactic acidosis, especially with Metformin and Glimepiride.
• Pregnancy - Generally not recommended during pregnancy. Consult your doctor; insulin is often preferred for glycemic control in pregnant women.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk and potentially affect the infant.
• Liver - Use with caution in patients with liver impairment; Metformin and Glimepiride metabolism can be affected, increasing the risk of side effects. Contraindicated in severe liver disease.
• Kidney - Contraindicated in severe renal impairment (e.g., eGFR <30 mL/min/1.73m²) due to increased risk of lactic acidosis with Metformin. Dose adjustment may be needed for other components in moderate impairment.
• Lung - Use with caution in patients with severe lung conditions, as it may exacerbate conditions that predispose to lactic acidosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.